Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies. [electronic resource]
Producer: 20130808Description: 133-44 p. digitalISSN:- 1551-4005
- Apoptosis -- drug effects
- Boronic Acids -- therapeutic use
- Bortezomib
- Cell Line, Tumor
- Dexamethasone -- toxicity
- Dimerization
- Drug Synergism
- Hematologic Neoplasms -- drug therapy
- Humans
- K562 Cells
- Lymphoma -- drug therapy
- NF-kappa B -- antagonists & inhibitors
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Proteasome Inhibitors -- therapeutic use
- Pyrazines -- therapeutic use
- RNA Interference
- RNA, Small Interfering -- metabolism
- Receptors, Glucocorticoid -- agonists
- Transcription Factor AP-1 -- antagonists & inhibitors
- Transcriptional Activation
- Triazoles -- therapeutic use
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.